Halozyme Therapeutics Inc. (NASDAQ: HALO) stock declined by 0.15% at last close whereas the HALO stock gains by 10.04% in the pre-market trading session. Halozyme is a pharmaceutical business that develops revolutionary ways to enhance patient outcomes and experiences for both new and current medicines.
>> 7 Top Picks for the Post-Pandemic Economy <<
HALO stock, Financial Highlights
Halozyme Therapeutics reported its second-quarter 2021 financial results. Here’s the summary:
- The revenue generated for the second quarter of 2021 was $136.5 million relative to $55.2 million for Q2 2021.
- The second quarter’s cost of product sales was $23.0 million whereas for the second quarter 2020 it was $5.7 million
- The research and development costs for Q2 2021 were $8.1 million, relative to $9.0 million in the second quarter of 2020.
- For the second quarter of 2021 selling, general, and administrative costs were $12.3 million while the values were $11.0 million in the second quarter of 2020.
- Operating income was $93.0 million on a GAAP basis in the second quarter of 2021, relative to $29.6 million in the second quarter of 2020.
- Net income was $91.5 million on a GAAP basis in the second quarter of 2021, relative to $25.8 million in Q2 of 2020.
- The non-GAAP net income in the second quarter of 2021 was $97.8 million, relative to $33.6 million in the second quarter of 2020.
- On June 30, 2021, cash, cash equivalents, and marketable securities totaled $755.3 million, up from $368.0 million on December 31, 2020.
Read More
Corporate Update
In the second quarter, HALO repurchased about 1.0 million shares of common stock for $48.8 million at an average value of $47.05, meeting its objective of $125 million in share repurchases at an average price of $44.43 in 2021.
HALO stock 2021 Financial Expectations
- Revenues are expected to be between $425 million to $445 million, a rise from the previous estimate of $375 to $395 million, reflecting a 59% to 66% year-over-year increase.
- GAAP Operating Income is anticipated between $260 million to $280 million, an increase of 80 percent to 94 percent year over year.
- GAAP Diluted Earnings per Share of $1.55 to $1.70, up from an earlier forecast of $1.25 to $1.40, reflecting 70 percent to 86 percent year-over-year increase.
- Non-GAAP Diluted Earnings per Share of $1.85 to $2.00, up from an earlier forecast of $1.55 to $1.70, representing 65% to 78% year-over-year increase.
